Molecular Biology for the Radiation Oncologist: the 5Rs of Radiobiology meet the Hallmarks of Cancer

Clinical Oncology

Volumn 19, Issue 8, 2007, Pages 561-571

  Harrington, K ^a,b   Jankowska, P ^a   Hingorani, M ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Hallmarks of cancer; molecular biology; radiobiology; targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; PACLITAXEL; TELOMERASE; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL CYCLE REGULATION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; RADIATION ONCOLOGY; RADIOBIOLOGY; RADIOTHERAPY; SIGNAL TRANSDUCTION;

EID: 34548145838     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.04.009     Document Type: Article

References (91)

1. Nutting C. Intensity-modulated radiotherapy (IMRT): the most important advance in radiotherapy since the linear accelerator?. Br J Radiol 76 910 (2003) 673
2. Barth R.F., and Joensuu H. Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation?. Radiother Oncol 82 2 (2007) 119-122
3. Greco C., and Wolden S. Current status of radiotherapy with proton and light ion beams. Cancer 109 7 (2007) 1227-1238
4. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 25 (2005) 5910-5917
5. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 19 (2004) 1945-1952
6. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
7. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 15 (1999) 1154-1161
8. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 15 (1999) 1137-1143
9. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355 9208 (2000) 949-955
10. Henk J.M. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol (R Coll Radiol) 9 5 (1997) 308-312
11. Bourhis J., Guigay J., Temam S., and Pignon J.P. Chemo-radiotherapy in head and neck cancer. Ann Oncol 17 Suppl 10 (2006) x39-x41
12. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 6 (2006) 567-578
13. RTOG (http://www.rtog.org/members/active.html).
14. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
15. Withers H.R. The four R's of radiotherapy. Adv Radiat Biol 5 (1975) 241-247
16. Steel G.G., McMillan T.J., and Peacock J.H. The 5Rs of radiobiology. Int J Radiat Biol 56 6 (1989) 1045-1048
17. Banath J.P., Macphail S.H., and Olive P.L. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 64 19 (2004) 7144-7149
18. Berry S.E., Garces C., Hwang H.S., et al. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Cancer Res 59 8 (1999) 1840-1845
19. Bishay K., Ory K., Lebeau J., Levalois C., Olivier M.F., and Chevillard S. DNA damage-related gene expression as biomarkers to assess cellular response after gamma irradiation of a human lymphoblastoid cell line. Oncogene 19 7 (2000) 916-923
20. Harrington K.J. Interactions between ionising radiation and drugs in head and neck cancer - how can we maximize the therapeutic index?. Curr Opin Investig Drugs 3 (2002) 807-811
21. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 6743 (1999) 464-468
22. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 2 (1996) 159-170
23. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 4260 (1976) 23-28
24. Renan M. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 7 (1993) 139-146
25. Hunter T. Oncoprotein networks. Cell 88 3 (1997) 333-346
26. Rommel C., and Hafen E. Ras - a versatile cellular switch. Curr Opin Genet Dev 8 4 (1998) 412-418
27. DiFiore P.P., Kraus M.H., Segatto O., King C.R., and Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237 (1987) 178-182
28. Fedi P., and Aaronson S.A. Growth factors (1997), Williams and Wilkins, Baltimore, MD
29. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 5430 (1999) 1028-1032
30. Lukashev M.E., and Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8 11 (1998) 437-441
31. Medema R.H., and Bos J.L. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 4 6 (1993) 615-661
32. Hagan M., Yacoub A., and Dent P. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clin Cancer Res 10 17 (2004) 5724-5731
33. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39 5 (2006) 469-478
34. Ashkenazi A., and Dixit V.M. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11 2 (1999) 255-260
35. Evan G., and Littlewood T. A matter of life and cell death. Science 281 5381 (1998) 1317-1322
36. Lotem J., and Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 10 6 (1996) 925-931
37. Thornberry N.A., and Lazebnik Y. Caspases: enemies within. Science 281 5381 (1998) 1312-1316
38. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 5381 (1998) 1309-1312
39. Sachs L., and Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood 82 1 (1993) 15-21
40. Harris C.C. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis 17 6 (1996) 1187-1198
41. Pennati M., Folini M., and Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28 6 (2007) 1133-1139
42. Grimes K.R., Warren G.W., Fang F., Xu Y., and St Clair W.H. Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncol Rep 16 4 (2006) 771-776
43. Guan H.T., Xue X.H., Dai Z.J., Wang X.J., Li A., and Qin Z.Y. Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol 12 18 (2006) 2901-2907
44. Kappler M., Taubert H., Bartel F., et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 13 1 (2005) 167-172
45. Karikari C.A., Roy I., Tryggestad E., et al. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther 6 3 (2007) 957-966
46. Kim D.W., Seo S.W., Cho S.K., et al. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of grade II chondrosarcoma cells. J Orthop Res 25 6 (2007) 820-828
47. Lu B., Mu Y., Cao C., et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64 8 (2004) 2840-2845
48. Song H., Xin X.Y., Xiao F., Wang D.T., Yue Q.H., and Han X. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol (2006) (in press)
49. Tanabe K., Kim R., Inoue H., Emi M., Uchida Y., and Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol 22 4 (2003) 875-881
50. Yamanaka K., Rocchi P., Miyake H., et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4 11 (2005) 1689-1698
51. Zhang B., Liu J.Y., Pan J.S., et al. Combined treatment of ionizing radiation with genistein on cervical cancer HeLa cells. J Pharmacol Sci 102 1 (2006) 129-135
52. Yamanaka K., Gleave M.E., Hara I., Muramaki M., and Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther 4 2 (2005) 187-195
53. Varner J.A., and Cheresh D.A. Integrins and cancer. Curr Opin Cell Biol 8 5 (1996) 724-730
54. Bouck N., Stellmach V., and Hsu S.C. How tumors become angiogenic. Adv Cancer Res 69 (1996) 135-174
55. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 3 (1996) 353-364
56. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 5178 (1994) 1582-1584
57. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 6423 (1993) 841-844
58. Newbold K., Partridge M., Cook G., et al. Advanced imaging applied to radiotherapy planning in head and neck cancer: a clinical review. Br J Radiol 79 943 (2006) 554-561
59. Overgaard J., and Horsman M.R. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 6 1 (1996) 10-21
60. Carrato A., Gallego-Plazas J., and Guillen-Ponce C. Anti-VEGF therapy: a new approach to colorectal cancer therapy. Expert Rev Anticancer Ther 6 10 (2006) 1385-1396
61. Langer C.J., and Natale R.B. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 32 6 Suppl 10 (2005) S23-S29
62. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9 6 (2003) 1957-1971
63. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
64. Datto M.B., Hu P.P., Kowalik T.F., Yingling J., and Wang X.F. The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol 17 4 (1997) 2030-2037
65. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 6494 (1994) 257-261
66. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 3 (1995) 323-330
67. Chin L., Pomerantz J., and DePinho R.A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 23 8 (1998) 291-296
68. Fynan T.M., and Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog 4 5 (1993) 493-540
69. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 1 (1996) 97-99
70. Hayflick L. Mortality and immortality at the cellular level. A review. Biochemistry (Mosc) 62 11 (1997) 1180-1190
71. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 33 5 (1997) 787-791
72. Bryan T.M. Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol 11 (1999) 318-324
73. Bryan T.M., Englezou A., Gupta J., Bacchetti S., and Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. Embo J 14 17 (1995) 4240-4248
74. Muniyappa K., and Kironmai K.M. Telomere structure, replication and length maintenance. Crit Rev Biochem Mol Biol 33 4 (1998) 297-336
75. Gu J., and Fang B. Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2 4 Suppl 1 (2003) S64-S70
76. Murofushi Y., Nagano S., Kamizono J., et al. Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: a promising implication of telomerase-dependent targeted cancer gene therapy. Int J Oncol 29 3 (2006) 681-688
77. Sporn M.B. The war on cancer. Lancet 347 9012 (1996) 1377-1381
78. Christofori G., Naik P., and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369 6479 (1994) 414-418
79. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 9 (1999) 1237-1241
80. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 91 4 (1997) 439-442
81. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001) 50-56
82. Liang Z., Wu T., Lou H., et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64 12 (2004) 4302-4308
83. Cox J.D., Pajak T.F., Asbell S., et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 27 3 (1993) 493-498
84. Hoffstetter S., Marchal C., Peiffert D., et al. Treatment duration as a prognostic factor for local control and survival in epidermoid carcinomas of the tonsillar region treated by combined external beam irradiation and brachytherapy. Radiother Oncol 45 2 (1997) 141-148
85. Kwong D.L., Sham J.S., Chua D.T., Choy D.T., Au G.K., and Wu P.M. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 39 3 (1997) 703-710
86. Moonen L., vd Voet H., de Nijs R., Horenblas S., Hart A.A., and Bartelink H. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 42 3 (1998) 525-530
87. Perez C.A., Grigsby P.W., Castro-Vita H., and Lockett M.A. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 32 5 (1995) 1275-1288
88. Robertson C., Robertson A.G., Hendry J.H., et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys 40 2 (1998) 319-329
89. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 1. J Clin Oncol 22 5 (2004) 777-784
90. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial -INTACT 2. J Clin Oncol 22 5 (2004) 785-794
91. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500